The ability of chidamide to kill DLBCL cells in culture was confirmed by others, who demonstrated that chidamide operated in a dose-dependent manner and interfered with the activation of STAT3 [178]. The gene discussed is STAT3; the disease is diffuse large B-cell lymphoma.